Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 54

1.

Increased endostatin generation and decreased angiogenesis via MMP-9 by tamoxifen in hormone dependent ovarian cancer.

Bendrik C, Karlsson L, Dabrosin C.

Cancer Lett. 2010 Jun 1;292(1):32-40. doi: 10.1016/j.canlet.2009.11.002. Epub 2009 Nov 26.

PMID:
19944523
2.
3.

Tamoxifen decreases extracellular TGF-beta1 secreted from breast cancer cells--a post-translational regulation involving matrix metalloproteinase activity.

Nilsson UW, Jönsson JA, Dabrosin C.

Exp Cell Res. 2009 Jan 1;315(1):1-9. doi: 10.1016/j.yexcr.2008.10.015. Epub 2008 Oct 28.

PMID:
18996114
4.

Gene transfer of matrix metalloproteinase-9 induces tumor regression of breast cancer in vivo.

Bendrik C, Robertson J, Gauldie J, Dabrosin C.

Cancer Res. 2008 May 1;68(9):3405-12. doi: 10.1158/0008-5472.CAN-08-0295.

5.

MMP-2 and MMP-9 activity is regulated by estradiol and tamoxifen in cultured human breast cancer cells.

Nilsson UW, Garvin S, Dabrosin C.

Breast Cancer Res Treat. 2007 May;102(3):253-61. Epub 2006 Oct 10.

PMID:
17031577
6.

Tamoxifen, flaxseed, and the lignan enterolactone increase stroma- and cancer cell-derived IL-1Ra and decrease tumor angiogenesis in estrogen-dependent breast cancer.

Lindahl G, Saarinen N, Abrahamsson A, Dabrosin C.

Cancer Res. 2011 Jan 1;71(1):51-60. doi: 10.1158/0008-5472.CAN-10-2289. Epub 2010 Nov 19.

7.

Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis.

Johnston SR, Boeddinghaus IM, Riddler S, Haynes BP, Hardcastle IR, Rowlands M, Grimshaw R, Jarman M, Dowsett M.

Cancer Res. 1999 Aug 1;59(15):3646-51.

8.

Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice.

Huang S, Van Arsdall M, Tedjarati S, McCarty M, Wu W, Langley R, Fidler IJ.

J Natl Cancer Inst. 2002 Aug 7;94(15):1134-42.

PMID:
12165638
9.

Characterization of new estrogen receptor destabilizing compounds: effects on estrogen-sensitive and tamoxifen-resistant breast cancer.

Hoffmann J, Bohlmann R, Heinrich N, Hofmeister H, Kroll J, Künzer H, Lichtner RB, Nishino Y, Parczyk K, Sauer G, Gieschen H, Ulbrich HF, Schneider MR.

J Natl Cancer Inst. 2004 Feb 4;96(3):210-8.

PMID:
14759988
10.

Benefits of complete polyamine deprivation in hormone responsive and hormone resistant MCF-7 human breast adenocarcinoma in vivo.

Leveque J, Foucher F, Havouis R, Desury D, Grall JY, Moulinoux JP.

Anticancer Res. 2000 Jan-Feb;20(1A):97-101.

PMID:
10769640
12.

The nature of tamoxifen action in the control of female breast cancer.

Kodama M, Kodama T.

In Vivo. 2001 Jul-Aug;15(4):319-25. Review.

PMID:
11695224
13.

EphA2 overexpression decreases estrogen dependence and tamoxifen sensitivity.

Lu M, Miller KD, Gokmen-Polar Y, Jeng MH, Kinch MS.

Cancer Res. 2003 Jun 15;63(12):3425-9.

14.

Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice.

Yao K, Lee ES, Bentrem DJ, England G, Schafer JI, O'Regan RM, Jordan VC.

Clin Cancer Res. 2000 May;6(5):2028-36.

15.

Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer.

Yabushita H, Shimazu M, Noguchi M, Kishida T, Narumiya H, Sawaguchi K, Noguchi M.

Oncol Rep. 2003 Jan-Feb;10(1):89-95.

PMID:
12469150
16.
17.

Reversal of tamoxifen resistance of human breast carcinomas in vivo by neutralizing antibodies to transforming growth factor-beta.

Arteaga CL, Koli KM, Dugger TC, Clarke R.

J Natl Cancer Inst. 1999 Jan 6;91(1):46-53.

PMID:
9890169
18.
19.
20.

Supplemental Content

Support Center